EuroPCR 2018 Roundup: Medtronic touts BP reductions, no major adverse events in renal denervation trial

Medtronic (NYSE:MDT) today released six-month results from a trial of its Symplicity Spyral renal denervation system exploring its use treating hypertensive patients who are already taking anti-hypertension medications, touting significant reductions in blood pressure and no major adverse safety events. Results were presented at the 2018 EuroPCR annual meeting in Paris and were published in The Lancet. In the trial, patients were prescribed up to three anti-hypertensive medications, including diuretics, calcium channel blockers, ACE/ARB inhibitors or beta blockers, the Fridley, Minn.-based company said. Patients were then randomized, with one arm receiving treatment with the Symplicity Spyral renal denervation system and one arm receiving a sham treatment. Data indicated that patients who received the renal denervation procedure had an average 9 mm Hg drop in 24-hour mean systolic ambulatory blood pressure at six months, which equals a 7.4 mmHg difference compared to patients in the sham control arm. Renal denervation patients also reported a 24-hour mean diastolic ABPM drop of 6 mm Hg, 4.1 mm Hg lower than those in the sham control arm, Medtronic said. Average office systolic blood pressure in patients who received treatment with the Symplicity system dropped 9.4 mm Hg, 6.8 mm Hg lower than those in the sham control arm. Diastolic OBP also declined 5.2 mm Hg, 3.5 mm Hg different than the control arm. “Data from the Spyral HTN-On Med study is important for the clinical...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blood Management Cardiac Implants Cardiovascular Clinical Trials Abbott Medtronic ReCor Medical Source Type: news